Though per- and polyfluoroalkyl substances (PFAS) make headlines daily, a new paper reveals that most studies finding links between PFAS exposure and human health harms are published without a press release and receive little or no media coverage. The analysis, published today in the journal Environmental Health, found that studies without any press attention receive fewer scholarly citations as well.
Back pain sufferers expected to increase by 36% over the next three decades, say researchers
Back pain is a common problem that impacts more than 619 million people globally and remains the leading cause of disability worldwide. In the next three decades, that number is expected to jump to 840 million people.
COVID-19 case studies offer insights into what it will take to combat misleading medical information online
A team of medical and public health leaders from the American Board of Internal Medicine, ABIM Foundation, and several respected institutions say COVID-19 case studies, among other examples, can inspire new recommendations aimed at combatting viral medical rumors and false or misleading information online.
New study shows potential benefits of normothermic machine perfusion in liver transplantation
A clinical trial comparing conventional low-temperature storage of transplant donor livers with storage at physiological body temperature has revealed promising results for the evolution of liver transplantation. Results from the trial, published this month in Annals of Surgery, show compelling findings that could potentially revolutionize the way we preserve and transplant donor livers.
Racial disparities discovered in patients with cardiac devices
Black patients with implantable cardioverter defibrillators (ICDs) have a significantly higher burden of disease than white patients with the same device, according to a new study from University of Rochester Medical Center (URMC) cardiology researchers. Analyzing data from clinical trials conducted over a 20-year period by the Clinical Cardiovascular Research Center (CCRC) at URMC, investigators concluded that not only did Black patients with ICDs tend to be significantly younger than white patients, but they also had a higher rate of post-implant cardiac events and risk of death.
How much of a difference is 988 making a year after its launch?
The national 988 Suicide & Crisis Lifeline has hit its one-year anniversary, and it appears that the public is increasingly turning to the number in times of darkness.
First study to directly compare gene mutation type in individuals with CHAMP1 disorder indicates key differences
New research led by the Seaver Autism Center for Research and Treatment at Mount Sinai has illuminated genetic differences among children with a rare neurodevelopmental condition and could point the way toward a precision medicine approach to caring for these children.
Redlining linked to higher heart failure risk among Black adults in U.S.
The risk of heart failure in the present day is higher among Black adults who live in U.S. ZIP codes historically impacted by redlining, according to research published today in Circulation. The analysis, published as part of the journal’s “Disparities in Cardiovascular Medicine Special Issue,” included more than 2.3 million adults from 2014-2019 who lived in U.S. communities with varying degrees of redlining, which began in the mid-1930s.
National poll: Less than half of parents utilize patient portal benefits for their children
For many busy families, online access to a child’s health provider for medical advice, health records or prescription refills is likely a convenient option.
Expert panel updates cancer and aging guidelines
In an effort to improve treatment outcomes and quality of life for older adults with cancer, researchers from City of Hope, one of the largest cancer research and treatment organizations in the United States, and colleagues across the country today released updated guidelines by the American Society of Clinical Oncology (ASCO) outlining the need to assess and manage vulnerabilities in patients aged 65 and older prior to prescribing chemotherapy, targeted therapy and/or immunotherapy.